Renal Cell Carcinoma CPG Mini Module - Management of Clear Cell Renal Cell Carcinoma with Large Metastatic Burden

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

Martin H. Voss, MD - Memorial Sloan Kettering Cancer Center, presents a case of a 67-year-old man with metastatic clear cell renal cell carcinoma (ccRCC) with symptomatic endobrachial disease.  This presentation addresses appropriate therapy for patients of poor risk, according to the IMDC model.  Dr. voss also addresses strengths and weaknesses associated with combination therapies, both immunotherapy combinations (IO/IO) and immunotherapy coupled with a tyrosine kinase inhibitor (IO/TKI).  Data from the CheckMate 214 and CLEAR trials are also addressed.  This mini module closes with a panel discussion of factors to consider when choosing an appropriate IO/TKI combination therapy. 

Run time: 12 minutes

Target Audience 

Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

SITC Online Education Disclaimer 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021). 
 
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.